Drug Trial Radar · NCT05668013
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Actual
Start
Jan 11, 2023
Primary completion
Jan 5, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Dec 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: * evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD * evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD * evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.
Conditions
- Crohn Disease
- Colitis, Ulcerative
Interventions
TEV-48574 Dose Regimen ADrug
Subcutaneous (sc) administration using a commercial sc infusion system
TEV-48574 Dose Regiment BDrug
Subcutaneous (sc) administration using a commercial sc infusion system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo scoreTime frame: Week 44
- Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's DiseaseTime frame: Week 44
Locations
93 sites in 16 countries. Site status is shown where the registry gives one.
Clinical Applications Laboratories Inc
San Diego, California
I.H.S. Health
Kissimmee, Florida
Endoscopic Research, Inc.
Orlando, Florida
Gastro Florida
Pinellas Park, Florida
Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee
Gurnee, Illinois
Gastroenterology Health Partners, PLLC
New Albany, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Gastroenterology Health Partners, PLLC - Central Louisville
Louisville, Kentucky
BVL Clinical Research
Liberty, Missouri
Washington University School of Medicine
St Louis, Missouri
Vector Clinical Trials
Las Vegas, Nevada
Dayton Gastroenterology, LLC - Beavercreek
Beavercreek, Ohio
Texas Digestive Specialists
Harlingen, Texas
Gastro Health & Nutrition - Katy
Katy, Texas
Gastroenterology Research of San Antonio LLC
San Antonio, Texas
Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake
Southlake, Texas
Tyler Research Institute, LLC
Tyler, Texas
Care Access
Salt Lake City, Utah
Medical University Vienna
Vienna, Austria
Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD
Gorna Oryahovitsa, Bulgaria
20th Diagnostic Consultancy Center, Sofia
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia
Sofia, Bulgaria
Military Hospital Brno
Brno, Czechia
GASTRO JeKa s.r.o.
Klatovy, Czechia
Hospital Slany
Slaný, Czechia
Israeli - Georgian Medical Research Clinic Healthycore LLC
Tbilisi, Georgia
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
Tbilisi, Georgia
University Hospital Schleswig-Holstein
Kiel, Germany
University Hospital Tuebingen
Tübingen, Germany
University Hospital Ulm
Ulm, Germany
Group Practice Jakobeit
Wipperfürth, Germany
Semmelweis University, Department of Internal Medicine and Hematology
Budapest, Hungary
Clinexpert Ltd. Budapest
Budapest, Hungary
Javorszky Odon Hospital Vac
Vác, Hungary
HaEmek Medical Center
Afula, Israel
Soroka University Medical Center
Beersheba, Israel
Hospital San Raffaele, IRCCS
Milan, Italy
ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo University
Milan, Italy
Clinical Institute Humanitas, IRCCS
Rozzano, Italy
Kokikai Tsujinaka Hospital Kashiwanoha, Department of Gastroenterology
Kashiwa, Japan
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.